Zydus gets FDA approval for generic mycophenolate mofetil
This article was originally published in Scrip
Executive Summary
Zydus Cadila has received US FDA approval to market mycophenolate mofetil tablets 500mg and mycophenolate mofetil capsules 250mg. The products are generic versions of Roche's CellCept, which is indicated for the prevention of organ rejection in patients receiving kidney, heart or liver transplants. Sales of mycophenolate mofetil tablets and capsules were $648 million and $316 million respectively last year. The Zydus group now has 46 FDA approvals and has filed 92 ANDAs so far. Mylan, which has also received approval for generic CellCept, said that it has commenced shipping both products.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet